In recent performance briefings and investor relations activities, more than 10 A-share listed companies, including Xiangyu Medical, MEDLANDER, BIOTEST BIOTECH, and ZKTECO, disclosed the latest developments in their brain-computer interface businesses. Some companies expect to achieve revenue contributions from their brain-computer interface businesses within the year, while others announced the upcoming launch of multiple new products, and some are seizing development opportunities through investment layouts. Looking ahead to the second half of the year, A-share listed companies related to brain-computer interfaces will further accelerate the pace of investment and product implementation. Local policies are also making efforts by adding medical service pricing items to clear commercial barriers, promoting the domestic brain-computer interface industry into a new stage of "technological breakthroughs + commercial implementation" dual-driven development
